Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Completed · Phase 3 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients

Key facts

Study ID

NCT00461292

Run by

Allergan

People needed

275

Starts

2007-05-01

Expected to finish

2010-04-01

Last updated by the study team

2015-10-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
• Inadequate response to anticholinergic medication used to treat overactive bladder

You may not qualify if…

• History or evidence of pelvic or urologic abnormality
• Previous or current diagnosis of bladder or prostate cancer
• Urinary tract infection at time of enrollment

Where it is running

• Study site — Middlebury, Connecticut, United States
• Study site — Rio de Janeiro, Brazil
• Study site — Victoria, British Columbia, Canada
• Study site — Salouël, France
• Study site — Milan, Italy
• Study site — Amsterdam, Netherlands
• Study site — Porto, Portugal
• Study site — Singapore, Singapore
• Study site — Pretoria, South Africa
• Study site — Santa Cruz de Tenerife, Spain
• Study site — Hualien City, Taiwan
• Study site — Scunthorpe, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.